-+ 0.00%
-+ 0.00%
-+ 0.00%
Eocene, Barcode Develop Aramchol Nanoparticle Formulation Targeting Liver, GI Tumor Microenvironment
Share
Listen to the news
Eocene, Barcode Develop Aramchol Nanoparticle Formulation Targeting Liver, GI Tumor Microenvironment
  • Eocene reported development of a tumor-targeted lipid nanoparticle formulation of Aramchol through subsidiary Galmed’s collaboration with Barcode Nanotech.
  • The formulation aims to target fibrosis-driving cells in liver and gastrointestinal tumors, potentially improving responses to immunotherapy and other standard treatments.
  • Previously reported clinical findings showed oral Aramchol improved liver fibrosis in NASH/MASH patients in the ARREST trial and ARMOR open-label extension.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EoCene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO98422) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending